Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 7, 2010, Pages 3283-3290

  Taïeb, David ^a   Sebag, F ^a   Farman Ara, B ^a   Portal, T ^a   Baumstarck Barrau, K ^b   Fortanier, C ^b   Bourrelly, M ^a   Mancini, J ^a,b   De Micco, C ^c   Auquier, P ^b   Conte Devolx, B ^a   Henry, J F ^a   Mundler, O ^a  

^a TIMONE HOSPITAL   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROID HORMONE; IODINE; LIOTHYRONINE; RADIOACTIVE IODINE; RECOMBINANT PROTEIN; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; BONE MARROW; BREAST; CLINICAL ARTICLE; CLINICAL TRIAL; COLON; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG DOSE REGIMEN; DRUG HALF LIFE; FEMALE; HUMAN; HYPOTHYROIDISM; LARGE INTESTINE; MALE; OVARY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION PROTECTION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; STOMACH; THYROGLOBULIN BLOOD LEVEL; THYROID HORMONE BLOOD LEVEL; URINALYSIS; WHOLE BODY SCINTISCANNING; ABLATION THERAPY; ADENOCARCINOMA; COMPARATIVE STUDY; HALF LIFE TIME; METABOLISM; METHODOLOGY; MULTIMODALITY CANCER THERAPY; PAPILLARY CARCINOMA; RADIOMETRY; THYROID GLAND; THYROID TUMOR; TREATMENT OUTCOME;

ABLATION TECHNIQUES; ADENOCARCINOMA, FOLLICULAR; CARCINOMA, PAPILLARY; COMBINED MODALITY THERAPY; HALF-LIFE; HUMANS; IODINE; IODINE RADIOISOTOPES; PROSPECTIVE STUDIES; RADIOMETRY; RECOMBINANT PROTEINS; THYROID GLAND; THYROID NEOPLASMS; THYROTROPIN; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 77954913804     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2528     Document Type: Article

References (32)

1. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142
2. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E 2008 Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941-1959
3. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787-803
4. Borson-Chazot F, Bardet S, Bournaud C, Conte-Devolx B, Corone C, D'Herbomez M, Henry JF, Leenhardt L, Peix JL, Schlumberger M, Wemeau JL; Expert Group for French Recommendations for the Management of Differentiated Thyroid Carcinomas of Vesicular Origin, Baudin E, Berger N, Bernard MH, Calzada-Nocaudie M, Caron P, Catargi B, Chabrier G, Charrie A, Franc B, Hartl D, Helal B, Kerlan V, Kraimps JL, Leboulleux S, Le Clech G, Menegaux F, Orgiazzi J, Perié S, Raingeard I, Rodien P, Rohmer V, Sadoul JL, Schwartz C, Tenenbaum F, Toubert ME, Tramalloni J, Travagli JP, Vaudrey C 2008 Guidelines for the management of differentiated thyroid carcinomas of vesicular origin. Ann Endocrinol (Paris) 69:472-486
5. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G 2003 Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 88:4110-4115
6. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Turco A, Mariani G 2006 Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun 27:627-632 (Pubitemid 44305303)
7. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932
8. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropinstimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542-3546 (Pubitemid 47435333)
9. Robbins RJ, Tuttle RM, Sonenberg M, Shaha A, Sharaf R, Robbins H, Fleisher M, Larson SM 2001 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin. Thyroid 11:865-869 (Pubitemid 32847944)
10. Taieb D, Sebag F, Cherenko M, Baumstarck-Barrau K, Fortanier C, Farman-Ara B, De Micco C, Vaillant J, Thomas S, Conte-Devolx B, Loundou A, Auquier P, Henry JF, Mundler O 2009 Quality of life changes and clinical outcomes in thyroid cancer patients undergoing radioiodine remnant ablation (RRA) with recombinant humanTSH (rhTSH): a randomized controlled study. Clin Endocrinol (Oxf) 71:115-123
11. Chianelli M, Todino V, Graziano FM, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E 2009 Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 160:431-436
12. Menzel C, Kranert WT, Döbert N, Diehl M, Fietz T, Hamscho N, Berner U, Grünwald F 2003 rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of 131I. J Nucl Med 44:1065-1068 (Pubitemid 39663381)
13. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW 2009 Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94:4171-4179
14. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ 2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764-770 (Pubitemid 351717542)
15. Taïeb D, Lussato D, Guedj E, Roux F, Mundler O 2006 Early sequential changes in serum thyroglobulin after radioiodine ablation for thyroid cancer: possible clinical implications for recombinant human thyrotropin-aided therapy. Thyroid 16:177-179
16. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654
17. 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med 49:1445-1450
18. Borget I, Remy H, Chevalier J, Ricard M, Allyn M, Schlumberger M, De Pouvourville G 2008 Length and cost of hospital stay of radioiodine ablation in thyroid cancer patients: comparison between preparation with thyroid hormone withdrawal and thyrogen. Eur J Nucl Med Mol Imaging 35:1457-1463
19. Fallouch S, Lejeune PJ, Barbaria J, Carayon P, Mallet B 2004 Urinary iodine analysis: an alternative method for digestion of urine samples. Clin Chem 50:780-782
20. Lassmann M, Luster M, Hänscheid H, Reiners C 2004 Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med 45:619-625
21. 131I in outpatients: a simplified method conforming to the Code of Federal Regulations, title 10, part 35.75. J Nucl Med 41:1868-1875
22. Jeevanram RK, Shah DH, Sharma SM, Ganatra RD 1982 Disappearance rate of endogenously radioiodinated thyroglobulin and thyroxine after radioiodine treatment. Cancer 49:2281-2284
23. 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med 49:845-852
24. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C 1996 Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med 37:606-612
25. Garsi JP, Schlumberger M, Ricard M, Labbé M, Ceccarelli C, Schvartz C, Henry-Amar M, Bardet S, Rubino C, de Vathaire F 25 February 2009 Health outcomes of children fathered by patients treated with radioiodine for thyroid cancer. Clin Endocrinol (Oxf) 10.1111/j.1365-2265.2009.03561.x
26. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP 2008 A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf) 69:479-490
27. 131I: the effect of changing from fixed time to exposure rate threshold. Health Phys 72:476-480
28. 131I in thyroid cancer patients. Health Phys 81:325-329
29. 131I. J Nucl Med 43:61-65
30. 131I) therapy for thyroid carcinoma. JAMA 283:2272-2274
31. 131I therapy: measured doses in family members. Health Phys 76:129-136
32. Monsieurs M, Thierens H, Dierckx RA, Casier K, De Baere E, De Ridder L, De Saedeleer C, De Winter H, Lippens M, van Imschoot S, Wulfrank D, Simons M 1998 Real-life radiation burden to relatives of patients treated with iodine-131: a study in eight centres in Flanders (Belgium). Eur J Nucl Med 25:1368-1376